Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

autophagy

- PMLiVE

Lynparza scores against pancreatic cancer

AZ and MSD drug success in BRCA-mutated disease

- PMLiVE

More good news, and some bad, for Merck’s Keytruda

A rare setback in phase 3 liver cancer trial

- PMLiVE

Roche’s rival to Bayer’s Vitrakvi gets speedy FDA review

CNS penetration could give edge over rival

- PMLiVE

Advair generics and acquisitions to hit GSK in 2019

Earnings to decline as company transforms

- PMLiVE

Trulicity’s ascent lifts Lilly

Diabetes treatment leads new product growth

- PMLiVE

Novo Nordisk preps for speedy oral GLP-1 drug filing

Needs to compete with rival's fast-growing Trulicity

- PMLiVE

Pfizer closes on EU approval of lung cancer drug Vizimpro

And AZ claims first with Forxiga in T1 diabetes

Sanofi reception

FDA adcomm split on Sanofi’s type 1 diabetes drug

Concerns rose after Zynquista-treated patients showed an eight-fold increase in DKA

- PMLiVE

GSK upbeat on its return to oncology market

Zejula signals comeback after four year hiatus

- PMLiVE

AstraZeneca unveils reorg, hires controversial José Baselga as cancer chief

Underlines importance of cancer drugs to company's future growth

- PMLiVE

Merck’s backing of NGM Bio yields NASH drug deal

Drug has potential in diabetes treatment as well

- PMLiVE

First-line ovarian approval cements AZ’s Lynparza lead

Also new data on recently approved kidney disease drug

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links